Recombinant Human Adiponectin receptor protein 2 (ADIPOR2)

What is the basic structure of ADIPOR2 and how does it differ from ADIPOR1?

The revised crystal structures show that ADIPOR1 presents large rearrangements of TM5 and icl2 compared to ADIPOR2, with the largest structural difference observed at the α-carbon of M268 TM5 (ADIPOR2) versus R257 TM5 (ADIPOR1) residues, showing a significant 17 Å shift . In the ADIPOR1 structure, TM5 is positioned away from the 7TM hydrophobic core with a 15 Å translation of the intracellular part . These structural differences may reflect distinct functional states or mechanisms despite both receptors possessing ceramidase activity.

What are the primary physiological functions of ADIPOR2?

ADIPOR2 plays critical roles in mediating glucose and lipid metabolism through its function as a receptor for adiponectin . One of its primary molecular functions is its intrinsic ceramidase activity, which catalyzes the hydrolysis of ceramide to produce sphingosine and free fatty acid (FFA) . This enzymatic activity has significant implications for cell signaling, as ceramides and sphingolipids are important bioactive molecules involved in various cellular processes.

ADIPOR2 also activates the ERK1/2 mitogen-activated protein kinase pathway, particularly in vascular smooth muscle cells, vascular endothelial cells, and hepatocytes . This signaling pathway is involved in cellular proliferation and differentiation, suggesting that ADIPOR2 may exert proliferative effects by activating Ras signaling pathways . Additionally, ADIPOR2 has been specifically identified as the main adiponectin receptor responsible for anti-fibrosis effects in liver, indicating its potential role in preventing liver fibrosis .

How can researchers effectively express and purify recombinant ADIPOR2 for structural and functional studies?

For effective expression and purification of recombinant ADIPOR2, researchers should consider a multi-step approach optimized for membrane proteins. Based on successful structural studies, expression systems using HEK293 cells have proven effective for producing functional ADIPOR2 . When crystallizing ADIPOR2, researchers have employed antibody fragment (scFv) co-expression strategies to stabilize the protein structure .

After purification, verification of functional activity should include ceramidase activity assays, as this represents a key function of properly folded ADIPOR2. Researchers should be aware that while ADIPOR2 possesses intrinsic ceramidase activity, this activity is relatively low and enhanced by adiponectin .

How is ADIPOR2 expression dysregulated across different cancer types, and what are the implications for cancer research?

Pan-cancer analysis reveals that ADIPOR2 expression is dysregulated across multiple cancer types, exhibiting both upregulation and downregulation patterns depending on the specific cancer . According to comprehensive studies, ADIPOR2 is upregulated in diffuse large B-cell lymphoma (DLBC), kidney chromophobe (KICH), brain lower grade glioma (LGG), pancreatic adenocarcinoma (PAAD), skin cutaneous melanoma (SKCM), testicular germ cell tumors (TGCT), and thymoma (THYM) . Conversely, it is downregulated in lung adenocarcinoma (LUAD), ovarian serous cystadenocarcinoma (OV), pheochromocytoma and paraganglioma (PCPG), thyroid carcinoma (THCA), uterine corpus endometrial carcinoma (UCEC), and uterine carcinosarcoma (UCS) .

Beyond expression levels, ADIPOR2 demonstrates significant correlations with tumor immune microenvironment factors and multiple immune checkpoint genes. It is predominantly positively correlated with TNFSF15, NRP1, ICOSLG, HHLA2, CD44, CD274, and CD200 . These associations suggest potential implications for immunotherapy response prediction and design, making ADIPOR2 a compelling target for cancer immunology research.

What is the mechanistic basis for ADIPOR2's ceramidase activity, and how can it be experimentally measured?

ADIPOR2's ceramidase activity is mediated through a zinc-dependent hydrolytic mechanism. Crystal structures reveal that ADIPOR2 contains a zinc binding site within its 7TM domain that coordinates the hydrolysis of the amide bond in ceramide . The molecular mechanism involves the positioning of the ceramide substrate such that its amide carbonyl contacts R278 (TM5) and Y328 (TM6) side chains, which function as typical carbonyl polarizing and oxyanion stabilizing residues in zinc-dependent hydrolases . This arrangement exposes the amide carbon to nucleophilic attack by zinc-bound water molecules observed in the crystal structure .

Molecular dynamics simulations provide further insight into the hydrolytic mechanism. In the presence of C18:1 ceramide, a fast rearrangement of the zinc binding site leads to direct coordination changes that facilitate the reaction . The substrate docking studies predict an energetically favorable binding mode of ceramides (C18:1 and C16:0) with the fatty acid moiety positioned within the receptor cavity and the sphingosine part extending into the cavity exposed to the cytoplasm .

For experimental measurement of ADIPOR2's ceramidase activity, researchers typically employ assays using fluorescently labeled ceramide substrates or direct measurement of reaction products (sphingosine and free fatty acids) using mass spectrometry or HPLC. It's important to note that the intrinsic ceramidase activity of ADIPOR2 is relatively low but is enhanced by adiponectin . This suggests that for accurate assessment of full enzymatic capacity, assays should include conditions both with and without adiponectin. Researchers should be aware that mutations in the zinc binding site (e.g., H191 in ADIPOR1 or H202 in ADIPOR2) can disrupt the ceramidase activity .

How do the signaling pathways activated by ADIPOR2 differ from those of ADIPOR1?

Despite their structural similarities, ADIPOR1 and ADIPOR2 exhibit distinct signaling profiles with overlapping yet unique downstream pathways. Both receptors can activate the ERK1/2 mitogen-activated protein kinase pathway, as demonstrated in primary vascular smooth muscle, vascular endothelial cells, and hepatocytes . Interestingly, RNA interference studies have shown that downregulating either ADIPOR1 or ADIPOR2 individually does not attenuate adiponectin-induced ERK1/2 activation, but simultaneous downregulation of both receptors does impair this response . This suggests redundancy in their capacity to activate this particular signaling cascade.

The ERK1/2 activation mechanism involves Src-dependent Ras activation as the dominant pathway, demonstrated by the finding that adiponectin causes rapid, PP2-sensitive activation of Ras, but not the cAMP-regulated small GTPase Rap1 . The signaling cascade also involves APPL1, an adapter protein that mediates ADIPOR1/R2 signaling, as downregulation of APPL1 impairs adiponectin-stimulated ERK1/2 activation .

While both receptors possess ceramidase activity, their structural differences may lead to distinct enzymatic efficiencies or substrate preferences. The revised crystal structures reveal that ADIPOR1 exhibits a more "open" conformation compared to ADIPOR2, which could affect substrate accessibility and processing . Furthermore, ADIPOR2 is more prominently associated with anti-fibrotic effects in liver, suggesting differential tissue-specific functions despite shared molecular activities .

For researchers investigating receptor-specific signaling, it's important to design experiments that can isolate the individual contributions of each receptor, possibly through receptor-specific knockdowns or antagonists combined with pathway-specific readouts.

What are the optimal approaches for studying ADIPOR2-ligand interactions?

Studying ADIPOR2-ligand interactions requires a multi-faceted approach that combines structural, biochemical, and computational methods. Based on successful research strategies, the following approaches are recommended:

For structural studies, X-ray crystallography has proven effective for determining ADIPOR2 structure in complex with ligands . The method involves co-crystallization of ADIPOR2 with ligands such as free fatty acids, which has revealed important binding sites within the receptor . When designing crystallography experiments, researchers should be aware that ADIPOR2 crystals often exhibit weak and highly anisotropic diffraction, necessitating data collection from multiple crystals and careful processing strategies .

Computational methods provide complementary insights into ligand binding. Molecular docking has successfully predicted energetically favorable binding modes for ceramides (C18:1 and C16:0) within ADIPOR2 . These predictions position the fatty acid moiety within the receptor cavity and the sphingosine part extending into the cytoplasm-exposed cavity . Molecular dynamics simulations further enhance understanding by revealing the dynamic behavior of the receptor-ligand complex and conformational changes associated with ligand binding .

Biochemical assays measuring ceramidase activity can indirectly assess ligand binding and functional activation. Since adiponectin enhances ADIPOR2's ceramidase activity, measuring this enhancement can provide insights into receptor-adiponectin interactions . Additionally, binding assays utilizing fluorescently labeled ligands or surface plasmon resonance can directly quantify binding affinities and kinetics.

How can researchers effectively use computational modeling to study ADIPOR2 structure and function?

Computational modeling has emerged as a powerful tool for studying ADIPOR2, particularly when combined with experimental structural data. Based on published research, the following computational approaches have proven valuable:

Molecular docking has successfully identified potential binding modes for ceramide substrates, providing insights into the orientation of these molecules within the ADIPOR2 binding pocket . For optimal results, researchers should use the highest resolution crystal structures available (e.g., the 2.4 Å structure) and docking software such as PLANTS, which has been used effectively in published studies .

All-atom molecular dynamics simulations (MDS) offer deeper insights into the dynamic behavior of ADIPOR2 and its interactions with ligands. These simulations have revealed important conformational changes associated with the hydrolytic mechanism, such as the rearrangement of the zinc binding site in the presence of ceramide substrates . When setting up MDS, researchers should carefully consider both the pre- and post-cleavage states to understand the complete enzymatic cycle .

System preparation for MDS typically involves embedding the receptor-ligand complex in a lipid bilayer to mimic the native membrane environment, followed by solvation and addition of counterions . The resulting system should be energy-minimized and equilibrated before production runs. For studying ADIPOR2's ceramidase activity, simulations of the receptor with intact ceramide as well as with the reaction products (sphingosine and free fatty acid) provide complementary insights .

To ensure biological relevance, computational predictions should be validated against experimental data whenever possible. Mutational studies targeting residues predicted to be important for ligand binding or catalysis can provide crucial validation of computational models.

What techniques are most effective for measuring ADIPOR2 expression and activation in different tissue types?

Measuring ADIPOR2 expression and activation across different tissues requires a combination of molecular, cellular, and physiological techniques. Based on established research methodologies, the following approaches are recommended:

For RNA expression analysis, quantitative PCR (qPCR) remains a gold standard. Public databases such as The Human Protein Atlas (THPA), TIMER2.0, and GEPIA2 have been used extensively to analyze ADIPOR2 expression across normal and tumor tissues . These resources leverage data from repositories like TCGA and GTEx, providing comprehensive expression profiles across multiple tissue types .

Protein-level expression can be assessed using immunohistochemistry or western blotting with antibodies specific to ADIPOR2. The UALCAN database has been utilized to analyze protein levels across tissues, offering a reference point for researchers . When designing immunodetection experiments, it's important to validate antibody specificity, as ADIPOR1 and ADIPOR2 share structural similarities that could lead to cross-reactivity.

For functional activation studies, measuring downstream signaling events provides insights into receptor activity. The ERK1/2 phosphorylation assay has been used successfully to monitor ADIPOR2 activation in response to adiponectin stimulation . This assay can be performed in primary cells from different tissues, providing tissue-specific activation profiles .

Ceramidase activity assays offer a direct measurement of ADIPOR2's enzymatic function. These assays can be performed using crude cell lysates from different tissue types, comparing activity with and without adiponectin stimulation . It's worth noting that both ADIPOR1 and ADIPOR2 possess adiponectin-sensitive intrinsic ceramidase activity, so controls to distinguish between the two receptors are essential .

How does ADIPOR2 expression correlate with tumor microenvironment and immunotherapy response?

ADIPOR2 expression demonstrates significant correlations with the tumor immune microenvironment across multiple cancer types, suggesting potential implications for immunotherapy response prediction. Pan-cancer analysis reveals that ADIPOR2 displays significant associations with cancer stemness, tumor immune microenvironment, and immune checkpoint genes .

Specifically, ADIPOR2 shows predominant positive correlations with several immune checkpoint genes, including TNFSF15, NRP1, ICOSLG, HHLA2, CD44, CD274 (PD-L1), and CD200 . The strong correlation with CD274 (PD-L1) is particularly noteworthy given the central role of PD-L1 in current immunotherapy approaches. These associations suggest that ADIPOR2 expression levels might serve as a biomarker for predicting response to checkpoint inhibitor therapies.

Interestingly, ADIPOR2 is mainly negatively correlated with several TNFR superfamily members, including TNFRSF4, TNFRSF25, TNFRSF14, TMIGD2, CD70, and CD48 . This differential correlation pattern with various immune markers suggests a complex role in modulating the immune microenvironment.

Despite these correlations with immune checkpoint genes, the direct evidence for ADIPOR2's role in predicting immunotherapy response in clinical cohorts remains limited. Researchers investigating this relationship should design studies that specifically assess ADIPOR2 expression in pre-treatment samples from patients receiving immunotherapy and correlate this with response outcomes. Such studies would provide more definitive evidence for ADIPOR2's utility as a predictive biomarker.

What is the relationship between ADIPOR2 and drug sensitivity in cancer treatment?

ADIPOR2 demonstrates significant associations with drug sensitivity across various cancer types, making it a potential biomarker for predicting treatment response and a target for therapeutic intervention. Comprehensive pan-cancer analysis has revealed that ADIPOR2 correlates with sensitivity to various anti-cancer drugs .

While specific drug-ADIPOR2 interactions are not detailed in the available search results, the established correlation suggests several potential mechanisms. First, ADIPOR2's ceramidase activity may influence cellular sphingolipid metabolism, which can affect membrane composition, cellular stress responses, and consequently, drug uptake and efficacy . Second, ADIPOR2-mediated signaling through the ERK1/2 pathway could interact with drug-induced signaling cascades, potentially enhancing or diminishing therapeutic effects depending on the specific drug mechanism .

For researchers investigating the relationship between ADIPOR2 and drug sensitivity, cell-based assays combining ADIPOR2 modulation (overexpression, knockdown, or pharmacological targeting) with drug treatment can provide direct evidence of functional interactions. Drug sensitivity assays using patient-derived xenografts or organoids with varying ADIPOR2 expression levels could offer more translational insights into the clinical relevance of these associations.

The identification of ADIPOR2 as a potential modulator of drug sensitivity opens avenues for combination therapy approaches. For instance, drugs targeting ADIPOR2 or its downstream pathways might sensitize resistant cancer cells to standard chemotherapeutic agents. Further research is needed to identify specific drug classes most affected by ADIPOR2 expression and to develop strategies for exploiting these relationships in clinical settings.

How might targeting ADIPOR2's ceramidase activity offer therapeutic potential for metabolic and inflammatory diseases?

ADIPOR2's intrinsic ceramidase activity represents a promising therapeutic target for metabolic and inflammatory diseases, given the central role of ceramides in these conditions. Ceramides are bioactive lipids implicated in insulin resistance, inflammation, and cellular stress responses, making their metabolism a key intervention point.

The ceramidase activity of ADIPOR2 catalyzes the hydrolysis of ceramide to produce sphingosine and free fatty acid, potentially reducing cellular ceramide levels . This activity is enhanced by adiponectin, suggesting that strategies to increase adiponectin levels or enhance its binding to ADIPOR2 might augment ceramidase activity and improve metabolic outcomes . Understanding the structural basis of this activity, including the zinc binding site and the substrate binding pocket, provides molecular targets for drug development .

Molecular dynamics simulations have revealed key aspects of ADIPOR2's hydrolytic mechanism, including the rearrangement of the zinc binding site and the positioning of ceramide for nucleophilic attack . These insights enable structure-based drug design approaches targeting either the enhancement of ceramidase activity (for conditions where ceramide reduction is beneficial) or its inhibition (where maintaining ceramide levels might be therapeutic).

For inflammatory conditions, ADIPOR2's potential anti-inflammatory effects might operate through multiple mechanisms. By reducing ceramide levels, ADIPOR2 activation could attenuate inflammatory signaling pathways activated by ceramides. Additionally, ADIPOR2's correlations with immune checkpoint genes suggest potential immunomodulatory effects that could be therapeutically exploited .

What are the current gaps in understanding ADIPOR2 function and how might they be addressed?

Despite significant advances in ADIPOR2 research, several critical knowledge gaps remain that warrant further investigation. One primary area requiring clarification is the complete substrate specificity profile of ADIPOR2's ceramidase activity. While it has been established that ADIPOR2 can hydrolyze ceramides, the current research does not fully characterize its enzymatic parameters or preference for different ceramide species . Future studies should systematically evaluate ADIPOR2's activity against ceramides of varying chain lengths and degrees of saturation using quantitative enzyme kinetics approaches.

Another significant gap concerns the precise mechanisms through which adiponectin enhances ADIPOR2's ceramidase activity. While this enhancement has been observed experimentally, the structural and molecular basis for this effect remains unclear . Combined structural studies (e.g., cryo-EM of adiponectin-ADIPOR2 complexes) and biochemical analyses could elucidate how adiponectin binding modulates receptor conformation and catalytic activity.

The physiological significance of the distinct conformational states observed in ADIPOR1 versus ADIPOR2 crystal structures remains to be fully understood . Are these differences reflective of unique functional roles, or do they represent different states within a common catalytic cycle? Time-resolved structural studies and spectroscopic approaches that can capture conformational dynamics may help resolve this question.

Additionally, the tissue-specific functions of ADIPOR2 require further investigation. While ADIPOR2 has been identified as particularly important for anti-fibrotic effects in liver, its roles in other tissues and pathological contexts need clarification . Tissue-specific knockout models and cell type-specific expression analyses would provide valuable insights into these specialized functions.

How might emerging technologies advance our understanding of ADIPOR2 structure-function relationships?

Emerging technologies offer exciting opportunities to address current limitations in ADIPOR2 research and deepen our understanding of its structure-function relationships. Cryo-electron microscopy (cryo-EM) represents a powerful approach for determining the structure of ADIPOR2 in different functional states and in complex with adiponectin or other binding partners. Unlike X-ray crystallography, which provided the initial ADIPOR2 structures but requires crystal formation , cryo-EM can capture proteins in more native-like environments and potentially reveal dynamic conformational changes associated with receptor activation.

Single-molecule fluorescence resonance energy transfer (smFRET) could provide unprecedented insights into the conformational dynamics of ADIPOR2 during substrate binding and catalysis. By strategically placing fluorescent probes on specific domains of the receptor, researchers could monitor real-time structural changes in response to adiponectin binding or during ceramide hydrolysis, potentially resolving the relationship between the distinct conformational states observed in crystal structures .

Advanced computational approaches such as machine learning and artificial intelligence hold promise for predicting ADIPOR2-ligand interactions and identifying novel modulators. Deep learning models trained on existing structural and biochemical data could generate hypotheses about binding modes, substrate preferences, and potential pharmacological targeting strategies that could then be validated experimentally.

CRISPR-based gene editing technologies enable precise manipulation of ADIPOR2 expression and structure in relevant cellular and animal models. CRISPR interference (CRISPRi) or activation (CRISPRa) systems allow for temporal control of ADIPOR2 expression, while base editing or prime editing permit the introduction of specific mutations to probe structure-function relationships without complete gene knockout.

Proteomics approaches, particularly proximity labeling techniques such as BioID or APEX2, could identify the complete interactome of ADIPOR2 in different cellular contexts. These approaches would reveal both stable and transient protein-protein interactions, potentially uncovering new components of ADIPOR2 signaling networks and regulatory mechanisms.

What novel therapeutic approaches targeting ADIPOR2 show the most promise for clinical development?

Emerging therapeutic approaches targeting ADIPOR2 span multiple modalities, each with distinct advantages for clinical development. Small molecule agonists that enhance ADIPOR2's ceramidase activity represent a promising approach for conditions associated with ceramide accumulation, such as metabolic syndrome, non-alcoholic steatohepatitis, and certain neurodegenerative disorders. The detailed structural insights into ADIPOR2's binding pocket and catalytic site provide a foundation for structure-based drug design of such agonists . Computational approaches like molecular docking and dynamics simulations can accelerate the identification of candidates with favorable binding properties and activity profiles .

Adiponectin mimetics offer another innovative approach. Since adiponectin enhances ADIPOR2's ceramidase activity , peptides or small molecules that mimic adiponectin's interaction with the receptor could provide therapeutic benefits while avoiding the challenges associated with protein therapeutics. These mimetics could be designed based on the critical binding interfaces identified through structural and biochemical studies.

For cancer applications, the complex relationship between ADIPOR2 expression and prognosis across different cancer types suggests that both agonistic and antagonistic approaches might be valuable, depending on the specific cancer context . The correlation between ADIPOR2 and immune checkpoint molecules further suggests that combination approaches with existing immunotherapies might enhance efficacy .

Gene therapy approaches targeting ADIPOR2 expression represent a longer-term but potentially transformative strategy. For conditions where ADIPOR2 downregulation contributes to pathology, adeno-associated virus (AAV) vectors carrying the ADIPOR2 gene could restore expression in affected tissues. Conversely, RNA interference or antisense oligonucleotides could reduce ADIPOR2 expression in contexts where it promotes disease progression.

Regardless of the specific approach, therapeutic development should consider the tissue-specific roles of ADIPOR2 and the potential for both on-target and off-target effects. The complex interplay between ADIPOR1 and ADIPOR2 signaling also necessitates careful evaluation of receptor selectivity to achieve the desired therapeutic outcomes while minimizing adverse effects.